Publication of the 2012 Registration Document

Paris, April 19, 2013 – BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to specialty and orphan pharma products in oncology and supportive care, today announced that its 2012 Registration Document, has been registered with the French Market Authorities *(Autorité des Marchés Financiers)* on April 18, 2013.

The Registration Document is available to the public free of charge upon request as per current legal regulations at BioAlliance Pharma's headquarters - 49 Boulevard du Général Martial Valin, 75015 Paris - and may be consulted at the *http://www.bioalliancepharma.com* website (under Investors/AMF Regulated Informations).

The annual financial report, the report of the Chairman of the Board of Directors on corporate governance and on internal control and risk management procedures, as well as the related auditors' report, Information on the fees paid to the statutory auditors in 2012, are included in the 2012 Registration Document.

About BioAlliance Pharma
A company dedicated to specialty and orphan products in the treatment of cancers and supportive care, with an approach focused on drug resistance. BioAlliance Pharma designs and develops innovative medicines mainly intended for hospital use and drugs in rare or orphan diseases. Created in 1997 and listed on the Euronext stock exchange in Paris in 2005, the company has ambitions to become a key player in these areas by linking innovation to patient needs. It possesses the key skills to identify, develop and register drugs in Europe and the United States.
For more information, visit the BioAlliance Pharma website at www.bioalliancepharma.com

BioAlliance Pharma has developed a portfolio of advanced products:
Specialty products:
Loramyc®/Oravig® (Oropharyngeal candidiasis in immune compromised patients): Approved in 26 countries (Europe, USA, Korea), marketed in Europe and the United States.
Sitavig® (Herpes labialis): Registered in the U.S. and in 8 European countries, undergoing process in other European countries.
Fentanyl Lauriad® (chronic pain in cancer patients): Positive preliminary clinical Phase I results

Orphan Oncology products
Livatag® /doxorubicine Transdrug™ (Hepatocellular carcinoma): Phase III
Validive® / clonidine Lauriad® (Mucositis post-chemotherapy and radiotherapy in head and neck cancer): Phase II
Biotherapy AMEP® (Invasive metastatic melanoma): Phase I

BioAlliance Pharma SA
Judith Greciet, CEO
Tel: +33 1 45 58 76 00
judith.greciet@bioalliancepharma.com
Nicolas Fellmann, CFO
Tel: +33 1 45 58 71 00
nicolas.fellmann@bioalliancepharma.com

ALIZE RP
Caroline Carmagnol
Tel: +33 6 64 18 99 59
caroline@alizerp.com
Christian Berg
Tel: +33 1 42 68 86 41
christian@alizerp.com